Phosphocreatine disodium hydrate

Name: Phosphocreatine disodium hydrate
Brand: MedChemExpress
SKU: HY-D0885D
Rating: 4.5 (1 reviews)

Cat. No.: HY-D0885D Purity: 99.57%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Phosphocreatine (disodium hydrate) is an organic compound found in vertebrate skeletal muscles. Phosphocreatine (disodium hydrate) enhances antioxidant activity, and activates the TAK1 pathway to protect the heart. Phosphocreatine (disodium hydrate) normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway. Phosphocreatine (disodium hydrate) Phosphocreatine (disodium hydrate) provides renal protection by suppressing Apoptosis and ROS (Reactive Oxygen Species) generation through ERK mediated mediated Nrf-2/HO-1 pathway..

For research use only. We do not sell to patients.

Phosphocreatine disodium hydrate Chemical Structure

CAS No. : 19333-65-4

Size	Stock	Quantity
Free Sample (0.1 - 0.5 mg)	Apply Now
5 mg	Get quote	Estimated Time of Arrival: December 31
10 mg	Get quote	Estimated Time of Arrival: December 31
25 mg	Get quote	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Phosphocreatine disodium hydrate:

Phosphocreatine Get quote
Sodium creatine phosphate dibasic tetrahydrate Get quote
Phosphocreatine disodium Get quote
Phosphocreatine dipotassium Get quote

1 Publications Citing Use of MCE Phosphocreatine disodium hydrate

•Toxicol Appl Pharmacol. 9 March 2022, 115971.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All MAP3K Isoform Specific Products:

View All Isoforms

MAP3K7/TAK1 MAP3K8/COT/Tpl2 MAP3K6/ASK2 MAP3K5/ASK1

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

View All ERK Isoform Specific Products:

View All Isoforms

ERK ERK1 ERK2 ERK5 ERK8

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

Non-salt form:
Phosphocreatine (0-1 mM, 24 h) reveals the effect of anti-oxidant, anti-apoptosis and anti-necroptosis to protect agaist DOX (Doxorubicin) (HY-15142A)-induced cardiomyocytes injury in H9c2 cells by targeting TAK1^[2].
Phosphocreatine (0-1 mM, 24 h) alleviates oxidative stress by increasing antioxidant activity, subsequently recovers expression level of TAK1 to baseline and reduces apoptosis and necroptosis in DOX-induced myocardial injury^[2].
Phosphocreatine (5-20 mM, 24 h) attenuates cell injury and inhibits apoptosis induced by MGO (Methylglyoxal) (HY-106634) in PC12 cell^[3].
Phosphocreatine (5-20 mM, 24 h) prevents loss of mitochondrial membrane permeability of MGO (Methylglyoxal) injured PC-12 cells^[3].
Phosphocreatine (5-20 mM, 2 h) exhibits the neuroprotective effects in PC-12 cells relying on normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway^[3].
Phosphocreatine (5-40 mM, 24 h) at different concentrations might contribute to protection of the NRK-52E cells against MGO-induced kidney injury^[4].
Phosphocreatine (10-40 mM, 4 h) suppresses kidney oxidative stress metabolites^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[3]^[4]

Cell Line:	PC-12, NRK-52E cells
Concentration:	5, 10, 20, 40 mM
Incubation Time:	2 h
Result:	Significantly suppressed the enhanced early apoptosis in PC-12 cells in a dose-dependent manner. Increased the expression of Bcl-2, procaspase-3 and procaspase-9 in NRK-52E cells. Decreased the expression of Bax and cleaved caspase-3 in NRK-52E cells. Suppressed karyorrhexis and karyopyknosis in NRK-52E cells. Decreased the apoptotic rate compared with MGO-treated cells in NRK-52E cells. Prevented the losing of MMP (mitochondrial membrane potential) in NRK-52E cells.

Cell Viability Assay^[3]^[4]

Cell Line:	PC-12, NRK-52E cells
Concentration:	0, 5, 10, 20, 40 mM
Incubation Time:	24 h
Result:	Was not toxic to PC-12 cells under the treatment conditions. Significantly increased PC-12 cell viability at the concentrations of 5, 10 and 20 mM compared with MGO (Methylglyoxal) (HY-106634) groups. Contributed to protection of the NRK-52E cells against MGO-induced kidney injury.

Western Blot Analysis^[3]^[4]

Cell Line:	PC-12, NRK-52E cells
Concentration:	20, 40 mM
Incubation Time:	24 h
Result:	Increased the expression levels of Akt, Nrf2 (nuclear factor (erythroid-derived-2)-like 2 (Nrf2)) and HO-1 (Hemeoxygenase-1) in PC12 cells. Increased the expression of nuclear Nrf2 levels, and decreased Nrf2 level in PC12 cells cytoplasm. Increased the expression of p-Akt, HO-1 and Nrf2 with compared with pre-treatment for 2 h with LY294002 (a PI3K inhibitor) in PC12 cells. Significantly increased Bcl-2 and procaspase-9 levels and decreased Bax, cleaved caspase-9 and cleaved caspase-3 C level in NRK-52E cells. Decreased the expression of p-ERK and increased the Nrf2 and HO-1 expressions in NRK-52E cells.

In Vivo

Non-salt form:
Phosphocreatine (200 mg/kg, i.p., once every other day, 7 weeks) not only alleviates oxidative stress and myocardial apoptosis, but also rescues myocardial necroptosis in DOX-induced cardiotoxicity of rat^[2].
Phosphocreatine (20-40 mg/kg, i.v., daily, 6 weeks) has a protective effect on the kidney tissues against diabetic nephropathy in SD (Sprague Dawley) rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague Dawley (SD) rats, i.p., normal saline, 3 times; i.p., DOX 2 mg/kg, 7 times; i.p., normal saline, 3 times ^[2]
Dosage:	200 mg/kg
Administration:	i.p., once every other day, 7 weeks
Result:	Improved the heart function abnormality. Lowered myocardial apoptosis. Recovered the expression of Nrf2, SOD, FoxO3a and diminished C-Casp3, Bax/Bcl2 in the myocardial tissue of rats. Markedly improved myocardial necroptosis, as indicated by decreasing expression of RIP3 and CaMKII. Increased expression level of TAK1.

Animal Model:	Male Sprague Dawley (SD) rats, i.p., 70 mg/kg (STZ(Streptozotocin) (HY-13753)), daily, 6 weeks ^[4]
Dosage:	20, 40 mg/kg
Administration:	i.p., daily, 6 weeks
Result:	Reduced hyperglycemia compared with STZ (Streptozotocin) (HY-13753) -treated rats. Increased the weight of rats gradually compared with STZ (Streptozotocin) (HY-13753) group. Decreased kidney weight index (kidney weight/body weight). Decreased MDA level and increased of GSH and SOD levels compared with STZ group. Decreased the apoptotic rate compared with MGO-treated groups.

Clinical Trial

Formula

C₄H₁₀N₃O₅P.xH₂O.2Na

CAS No.

19333-65-4

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)CN(C(NP(O[Na])(O[Na])=O)=N)C.O.[x]

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Animals

Endogenous metabolite

skeletal muscles of vertebrates

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 116.67 mg/mL (Need ultrasonic)

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.57%

Select Batch:

Data Sheet (281 KB) SDS (393 KB)

COA (249 KB) HNMR (241 KB) CNMR (257 KB) RP-HPLC (278 KB) MS (70 KB)

Handling Instructions (2659 KB)

References

[1]. Feldman EB, et al. Creatine: a dietary supplement and ergogenic aid. Nutr Rev. 1999 Feb;57(2):45-50. [Content Brief]

[2]. Wang C, et al. Phosphocreatine attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and activating TAK1 to promote myocardial survival in vivo and in vitro. Toxicology. 2021 Aug;460:152881. [Content Brief]

[3]. Li H, et al. Neuroprotective effect of phosphocreatine on oxidative stress and mitochondrial dysfunction induced apoptosis in vitro and in vivo: Involvement of dual PI3K/Akt and Nrf2/HO-1 pathways. Free Radic Biol Med. 2018 May 20;120:228-238. [Content Brief]

[4]. Shopit A, et al. Protection of diabetes-induced kidney injury by phosphocreatine via the regulation of ERK/Nrf2/HO-1 signaling pathway. Life Sci. 2020 Feb 1;242:117248. [Content Brief]